As survival rates for children treated for childhood cancers become significantly better, the
focus is increasingly on determining the late effects of treatments and the best ways to …

Purpose: Tisagenlecleucel is an anti-CD19 chimeric antigen receptor (CAR19) T-cell
therapy approved for the treatment of children and young adults with relapsed/refractory (r/r) …

PURPOSE To improve the outcomes of patients with T-cell acute lymphoblastic leukemia (T-
ALL) and lymphoblastic lymphoma (T-LL), the proteasome inhibitor bortezomib was …

Tisagenlecleucel is a chimeric antigen receptor–T cell therapy that facilitates the killing of
CD19+ B cells. A model was developed for the kinetics of tisagenlecleucel and the impact of …

Background: CTL019 is an investigational therapy derived from autologous T-cells
expressing a CD19-specific chimeric antigen receptor (CAR). A single center, phase I/IIa trial …

Original research: Pooled safety analysis of tisagenlecleucel in children and young adults with
B cell acute lymphoblastic leukemia - PMC Back to Top Skip to main content NIH NLM Logo …

Tisagenlecleucel is indicated for pediatric and young adult patients with relapsed/refractory
(r/r) B-cell acute lymphoblastic leukemia (B-ALL) and adult patients with r/r diffuse large B …

Over the past 50 years, numerous advances in treatment have produced dramatic increases
in the cure rates of pediatric leukemias. Despite this progress, the majority of children with …

Background The treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in
children is challenging and new treatment options are needed. Bortezomib is a proteasome …

Hypersensitivity to pegaspargase is associated with inferior survival in pediatric patients with
acute lymphoblastic leukemia and lymphoblastic lymphoma. In the past year, drug‐supply …